Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).
百慕大汉密尔顿，2024 年 5 月 7 日（GLOBE NEWSWIRE）— Kiniksa 制药有限公司 纳斯达克股票代码：KNSA）今天宣布，管理层将在太平洋时间2024年5月14日星期二上午10点40分（美国东部时间下午1点40分）参加美国银行证券2024年医疗保健会议的炉边谈话。
A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa演讲的网络直播可通过该公司网站的 “投资者与媒体” 栏目观看，网址为 www.kiniksa.com。该活动的重播也将在活动结束后的大约48小时内在Kiniksa的网站上公布。
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
关于 Kiniksa
Kiniksa是一家处于商业阶段的生物制药公司，专注于发现、收购、开发和商业化治疗药物，以帮助患有虚弱性疾病、医疗需求严重未得到满足的患者。Kiniksa 的免疫调节资产 ARCALYST、abiprubart和mavrilimumab基于强有力的生物学原理或经过验证的机制，靶向一系列未得到充分治疗的心血管和自身免疫疾病，并具有分化潜力。欲了解更多信息，请访问 www.kiniksa.com。
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc.
ARCALYST 是 Regeneron Pharmicals, Inc. 的注册商标
|
Every Second Counts! Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
|
每一秒都很重要！ Kiniksa 投资者和媒体联系人 瑞秋弗兰克 (339) 970-9437 rfrank@kiniksa.com |